14.1 Chronic Disease Management and Secondary Prevention

14.1 Chronic Disease Management and Secondary Prevention

High-Yield Exam Focus: On the ANCC CMGT-BC examination, chronic disease management questions test the synthesis of clinical guidelines, disease staging systems, and multidisciplinary care coordination workflows. Candidates must master the Wagner Chronic Care Model (CCM) and its six core domains, the four foundational pillars of Guideline-Directed Medical Therapy (GDMT) in Heart Failure with Reduced Ejection Fraction (including the critical 36-hour ACEI-to-ARNI washout rule), GOLD ABE staging and inhaler technique in COPD, individualized glycemic targets, hypoglycemia protocols (Rule of 15), and sick-day management in Diabetes, and KDIGO staging, nephrotoxic avoidance, and non-dominant arm vein preservation in Chronic Kidney Disease (CKD).

---

Foundations of Chronic Disease Management & High-Utilizer Populations

Chronic illnesses are the paramount drivers of morbidity, functional decline, and healthcare expenditure in modern healthcare systems. In population health analytics, healthcare resource consumption demonstrates an extreme Pareto distribution: approximately 5% of patients (the high-need, high-cost cohort) account for roughly 50% of total healthcare expenditures, primarily through recurrent emergency department visits, acute hospital readmissions, and prolonged post-acute stays.

┌────────────────────────────────────────────────────────────────────────┐
│               POPULATION HEALTH UTILIZATION PYRAMID                    │
├────────────────────────────────────────────────────────────────────────┤
│    ▲  [Top 5% Cohort: >50% Total Cost]                                 │
│   / \   Complex Multimorbidity (HF, COPD, ESRD, Diabetes + SDOH Gaps) │
│  /───\  --> Intensive Case Management, Telemonitoring, GDMT Titration  │
│ /     \ [Rising Risk 15–20%: ~30% Total Cost]                          │
│/───────\  Emerging Chronic Conditions --> Targeted Disease Management │
││ Low-Risk / Healthy 75–80%: <20% Total Cost                           │
││  --> Universal Primary Prevention & Annual Wellness Surveillance      │
└┴───────────────────────────────────────────────────────────────────────┘

Nurse case managers serve as the central clinical integrators for these vulnerable individuals. The ultimate objective of chronic disease case management is not merely episodic crisis intervention, but the proactive stabilization of underlying pathophysiology, enhancement of patient self-efficacy, mitigation of social determinants of health (SDOH) barriers, and systematic facilitation of longitudinal care across inpatient, ambulatory, home health, and community domains.

---

The Wagner Chronic Care Model (CCM)

Developed by Edward Wagner and colleagues at the MacColl Center for Health Care Innovation, the Chronic Care Model (CCM) is the premier evidence-based structural framework for organizing healthcare delivery to meet the multifaceted needs of chronically ill individuals. The CCM identifies six essential, interdependent elements that interact to transform acute, reactive care into proactive, planned, and population-based chronic care.

┌────────────────────────────────────────────────────────────────────────┐
│                      WAGNER CHRONIC CARE MODEL                         │
├────────────────────────────────────────────────────────────────────────┤
│                             COMMUNITY                                  │
│    ┌──────────────────────────────────────────────────────────────┐    │
│    │               Resources and Policies Linkages                │    │
│    └──────────────────────────────┬───────────────────────────────┘    │
│                                   │                                    │
│                        HEALTH SYSTEM / ORGANIZATION                    │
│    ┌──────────────────────────────────────────────────────────────┐    │
│    │  Health System Leadership, Incentives & Safety Culture       │    │
│    ├──────────────────────────────┬───────────────────────────────┤    │
│    │    Self-Management Support   │    Delivery System Design     │    │
│    ├──────────────────────────────┼───────────────────────────────┤    │
│    │       Decision Support       │  Clinical Information Systems │    │
│    └──────────────────────────────┴───────────────────────────────┘    │
│                                   │                                    │
│           ┌───────────────────────┴───────────────────────┐            │
│           ▼                                               ▼            │
│   Informed, Activated                            Prepared, Proactive   │
│         Patient                                     Practice Team      │
│           │                                               │            │
│           └───────────────────────┬───────────────────────┘            │
│                                   │                                    │
│                                   ▼                                    │
│                        PRODUCTIVE INTERACTIONS                         │
│                                   │                                    │
│                                   ▼                                    │
│                   IMPROVED CLINICAL & FUNCTIONAL                       │
│                             OUTCOMES                                   │
└────────────────────────────────────────────────────────────────────────┘

The Six Core Elements Deconstructed

1. Health System Organization & Leadership:

   • Structural Focus: Fostering an institutional culture, quality improvement leadership, and financial incentive structure that visibly prioritizes chronic care excellence over volume-driven fee-for-service production.
   • Case Management Translation: Case management executives align institutional performance metrics with value-based purchasing (VBP) and Medicare Merit-based Incentive Payment System (MIPS) standards, securing dedicated resources for transitional care navigators, telemonitoring platforms, and multidisciplinary outpatient clinics.

2. Clinical Information Systems:

   • Structural Focus: Electronic registries and analytical platforms that track individual patient data as well as aggregate population health performance.
   • Case Management Translation: Case managers utilize disease-specific registries to query paneled cohorts, identify preventive care gaps (e.g., overdue diabetic foot evaluations or unmeasured A1c levels), track post-discharge transition intervals, and automate clinical alerts for abnormal diagnostic or laboratory values.

3. Delivery System Design:

   • Structural Focus: Structuring the clinical practice workflow, multidisciplinary team roles, and appointment logistics to separate scheduled, proactive chronic care management from reactive, acute illness encounters.
   • Case Management Translation: Case managers lead interprofessional team huddles, conduct planned comprehensive visits, delegate routine data collection to unlicensed assistive personnel (UAP) within legal scopes of practice, provide cultural and linguistic concordant communication, and coordinate proactive follow-up schedules.

4. Decision Support:

   • Structural Focus: Integrating evidence-based, guideline-directed standards into daily clinical practice through clinical decision support (CDS) algorithms, order sets, provider education, and specialist collaboration.
   • Case Management Translation: Case managers embed Guideline-Directed Medical Therapy (GDMT) checklists directly into electronic health records (EHR), ensure that clinical protocols reflect the latest professional society consensus, and facilitate timely physician-to-physician or specialist consultations for complex multimorbid cases.

5. Self-Management Support:

   • Structural Focus: Empowering patients and family caregivers with the skills, confidence, information, and problem-solving tools necessary to manage their chronic illnesses effectively on a day-to-day basis.
   • Case Management Translation: Case managers conduct patient-centered goal setting, deploy structured action plans (such as Traffic Light/Stoplight symptom tools), execute Teach-Back assessments, teach self-monitoring (blood glucose, blood pressure, daily weights), and link patients to peer-support networks.

6. Community Resources & Linkages:

   • Structural Focus: Establishing formal institutional partnerships and bidirectional communication channels with community-based organizations, public health agencies, and municipal services to address social determinants of health (SDOH).
   • Case Management Translation: Case managers actively connect patients to food pharmacies, medical transportation vouchers, exercise programs (e.g., SilverSneakers), adult day health centers, utility assistance programs, and local housing coalitions to remove external barriers to clinical adherence.

The Ultimate Goal of the CCM

The Chronic Care Model explicitly posits that high-quality chronic disease care is achieved only when productive interactions occur between an informed, activated patient (possessing knowledge, confidence, and self-management skills) and a prepared, proactive practice team (possessing comprehensive patient data, clinical decision support, and dedicated workflow time at the point of care).

---

Congestive Heart Failure (HF) Management & GDMT Protocols

Heart failure is a primary clinical condition monitored under the CMS Hospital Readmissions Reduction Program (HRRP). Effective nursing case management demands mastery of structural progression versus functional limitations, the four pharmacological pillars of Guideline-Directed Medical Therapy (GDMT), strict daily weight monitoring, and symptom action planning.

Clinical Staging: ACC/AHA Stages vs. NYHA Functional Classification

A critical distinction tested on the CMGT-BC exam is the fundamental difference between the American College of Cardiology/American Heart Association (ACC/AHA) stages and the New York Heart Association (NYHA) functional classes:

• ACC/AHA Stages (A, B, C, D): Reflect the structural development and anatomical progression of heart failure. Progression across ACC/AHA stages is strictly unidirectional and irreversible; once a patient progresses to Stage C, they remain Stage C indefinitely, even if their symptoms completely resolve on medical therapy.
• NYHA Functional Classes (I, II, III, IV): Reflect the patient's subjective symptom severity, functional exercise tolerance, and quality of life. NYHA functional class is dynamic and bidirectional; an effectively treated patient can transition from NYHA Class IV back to Class II or Class I as compensation is restored.

The Four Foundational Pillars of GDMT in HFrEF (LVEF ≤40%)

Current ACC/AHA clinical practice guidelines mandate the rapid, concurrent initiation and uptitration of four foundational drug classes for all patients with Heart Failure with Reduced Ejection Fraction (HFrEF; LVEF ≤40%), proven to dramatically decrease all-cause mortality and hospital readmissions:

┌────────────────────────────────────────────────────────────────────────┐
│              THE FOUR FOUNDATIONAL GDMT PILLARS FOR HFrEF              │
├──────────────────────────────────┬─────────────────────────────────────┤
│ 1. RENIN-ANGIOTENSIN INHIBITOR   │ 2. EVIDENCE-BASED BETA-BLOCKER      │
│    • ARNI (Sacubitril/Valsartan) │    • Carvedilol                     │
│      (First-Line; Superior)      │    • Metoprolol Succinate ER        │
│    • ACEI or ARB if ARNI         │    • Bisoprolol                     │
│      intolerant/unaffordable     │    (Initiate ONLY when euvolemic;   │
│    *MANDATORY 36-HOUR WASHOUT*   │     never in acute decompensation!) │
│    when switching from ACEI!     │                                     │
├──────────────────────────────────┼─────────────────────────────────────┤
│ 3. MINERALOCORTICOID RECEPTOR    │ 4. SGLT2 INHIBITOR                  │
│    ANTAGONIST (MRA)              │    • Dapagliflozin                  │
│    • Spironolactone              │    • Empagliflozin                  │
│    • Eplerenone                  │    (Recommended for ALL HFrEF       │
│    (Monitor K+ and eGFR;         │     patients REGARDLESS of diabetes │
│     contraindicated if K >5.0    │     status; promotes osmotic        │
│     or eGFR <30 mL/min/1.73m²)   │     diuresis & cardiorenal benefit) │
└──────────────────────────────────┴─────────────────────────────────────┘

High-Yield GDMT Clinical Pearls for Case Managers

1. The 36-Hour Washout Rule: Angiotensin Receptor-Neprilysin Inhibitors (ARNI; sacubitril/valsartan) are preferred over ACE inhibitors or ARBs. When switching a patient from an ACE inhibitor (e.g., lisinopril, enalapril, ramipril) to an ARNI, a strict 36-hour washout period is legally and clinically mandatory. Sacubitril inhibits neprilysin (which degrades bradykinin), and ACE inhibitors also block bradykinin degradation; concurrent administration causes massive bradykinin accumulation, triggering fatal angioedema. Switching from an ARB to an ARNI does not require a washout period because ARBs do not inhibit bradykinin degradation.
2. Evidence-Based Beta-Blockers: Only three specific beta-blockers possess clinical trial evidence for mortality reduction in HFrEF: Carvedilol, Metoprolol Succinate extended-release (not metoprolol tartrate!), and Bisoprolol. Beta-blockers must be initiated at low doses and uptitrated slowly every 2 weeks. Exam Safety Rule: Beta-blockers must be initiated only when the patient is clinically stable and euvolemic (dry). Initiating beta-blockers during an acute, wet, decompensated state worsens pulmonary congestion and causes cardiogenic shock.
3. MRAs: Spironolactone and eplerenone block aldosterone receptors, halting myocardial fibrosis. Case managers must ensure baseline and regular follow-up monitoring of serum potassium and kidney function at 1, 4, and 12 weeks post-initiation. MRAs are contraindicated if baseline serum potassium exceeds 5.0 mEq/L or eGFR is <30 mL/min/1.73m².
4. SGLT2 Inhibitors: Dapagliflozin and empagliflozin provide profound cardiorenal benefits, reducing cardiovascular mortality and heart failure hospitalizations. They are prescribed for all symptomatic HFrEF patients regardless of glycemic status.

Daily Weight Monitoring, Sodium, and Fluid Protocols

• Daily Morning Weight Technique: Instruct the patient to weigh themselves every morning immediately upon waking, after emptying the bladder, before eating breakfast or drinking liquids, wearing the same light clothing (or naked), using the same calibrated digital scale placed on a hard, uncarpeted surface, and logging the weight immediately in a logbook or mobile health app.
• The Critical Clinical Red Flag Thresholds:
  • A weight gain of >2 pounds in 24 hours (overnight), OR
  • A weight gain of >5 pounds in one week.
  • These thresholds indicate occult intravascular fluid accumulation long before the clinical onset of gross peripheral edema or dyspnea, serving as the trigger for Yellow Zone action.
• Dietary Sodium & Fluid Restrictions: Standard sodium intake is restricted to <2,000 to 2,300 mg/day. Routine fluid intake is typically limited to 1.5 to 2.0 liters/day (48–64 oz), particularly in patients with advanced NYHA Class III/IV disease, persistent edema, or dilutional hyponatremia (serum sodium <130 mEq/L).

Stoplight (Traffic Light) Action Plan for Heart Failure

---

Chronic Obstructive Pulmonary Disease (COPD) Management

COPD is characterized by persistent, non-reversible airflow limitation resulting from chronic airway inflammation and alveolar destruction. Confirmatory diagnosis requires post-bronchodilator spirometry demonstrating an FEV1/FVC ratio <0.70.

Staging and Assessment: The Updated GOLD ABE Paradigm

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) evaluates disease severity across two distinct axes:

1. Spirometric Airflow Limitation Severity (GOLD 1–4): Based on post-bronchodilator FEV1 percentage of predicted normal:
   • GOLD 1 (Mild): FEV1 ≥80% predicted
   • GOLD 2 (Moderate): 50% ≤ FEV1 < 80% predicted
   • GOLD 3 (Severe): 30% ≤ FEV1 < 50% predicted
   • GOLD 4 (Very Severe): FEV1 <30% predicted
2. The GOLD ABE Clinical Assessment Framework: Guides maintenance pharmacotherapy based on exacerbation history and symptom burden (measured via the Modified Medical Research Council [mMRC] dyspnea scale or COPD Assessment Test [CAT]):

┌────────────────────────────────────────────────────────────────────────┐
│                     GOLD ABE CLASSIFICATION MATRIX                     │
├──────────────────────────────────────┬─────────────────────────────────┤
│ EXACERBATION HISTORY                 │ SYMPTOM BURDEN & IMPACT         │
│ (Past 12 Months)                     │ Low Symptoms: mMRC 0-1, CAT <10 │
│                                      │ High Symptoms: mMRC ≥2, CAT ≥10 │
├──────────────────────────────────────┼─────────────────────────────────┤
│ ≥2 Moderate Exacerbations            │            GROUP E              │
│ OR                                   │    (High Exacerbation Risk)     │
│ ≥1 Exacerbation leading to Hospital  │    *Initial Therapy: LABA+LAMA* │
│ Admission                            │   (Add ICS only if eos ≥300)    │
├──────────────────────────────────────┼────────────────┬────────────────┤
│ 0 to 1 Moderate Exacerbations        │    GROUP A     │    GROUP B     │
│ (Not leading to Hospital Admission)  │ (Low Symptoms, │(High Symptoms, │
│                                      │   Low Risk)    │   Low Risk)    │
│                                      │ Initial: Single│ Initial: Dual  │
│                                      │ Bronchodilator │ (LABA + LAMA)  │
└──────────────────────────────────────┴────────────────┴────────────────┘

Evidence-Based Pharmacotherapy Rules in COPD

• Dual Bronchodilation (LABA + LAMA): The combination of a Long-Acting Beta2-Agonist (LABA; e.g., formoterol, salmeterol) plus a Long-Acting Muscarinic Antagonist (LAMA; e.g., tiotropium, umeclidinium) is the foundation of maintenance therapy for both Group B and Group E patients, offering superior lung deflation, symptom control, and exacerbation reduction compared to monotherapy.
• Inhaled Corticosteroids (ICS): Inhaled corticosteroids (e.g., fluticasone, budesonide) are never used as monotherapy in COPD (Grade A evidence), as they provide no disease-modifying benefit and significantly increase the risk of bacterial pneumonia. ICS is added to LABA+LAMA (triple therapy) strictly for patients in Group E who exhibit a peripheral blood eosinophil count ≥300 cells/µL or who suffer frequent hospitalizations despite dual bronchodilators.

Inhaler Technique & Educational Mastery

Studies reveal that over 70% of COPD patients make critical technique errors when using their inhalation devices, leading to negligible lung deposition and frequent exacerbations. Case managers must evaluate and teach device-specific mechanics:

Comprehensive Case Management Interventions in COPD

1. Smoking Cessation (The 5 A's): Tobacco cessation is the only clinical intervention proven to arrest the accelerated annual decline of FEV1. Case managers execute the 5 A's framework:
   • Ask: Systematically identify and document tobacco use status at every encounter.
   • Advise: Urge tobacco cessation with strong, clear, personalized clinical advice.
   • Assess: Determine the patient's willingness and readiness to make a quit attempt.
   • Assist: Provide practical behavioral counseling and coordinate combined pharmacotherapy: Nicotine Replacement Therapy (NRT) (patch paired with short-acting gum/lozenge) combined with Varenicline (Chantix; partial nicotinic acetylcholine receptor agonist) or Bupropion SR (Zyban).
   • Arrange: Schedule follow-up contact within 1 week of the designated quit date.
2. Pulmonary Rehabilitation: A comprehensive, multidisciplinary outpatient intervention combining aerobic exercise conditioning, upper-body resistance training, nutritional counseling, psychosocial support, and breathing retraining (pursed-lip breathing to create positive end-expiratory backpressure and prevent airway collapse; diaphragmatic breathing). Proven to significantly reduce dyspnea, improve functional exercise tolerance (6-minute walk distance), and reduce 30-day readmissions post-hospitalization.
3. COPD Acute Exacerbation Action Plans: An exacerbation is identified using the Anthonisen Criteria (worsening dyspnea, increased sputum volume, and increased sputum purulence). Case managers ensure high-risk patients have home "rescue packs":
   • Oral Systemic Corticosteroids: Prednisone 40 mg daily for 5 days (shorter 5-day courses are as clinically effective as 14-day tapers with dramatically fewer adverse metabolic effects).
   • Targeted Antibiotics: Prescribed when sputum purulence is present along with increased dyspnea or volume (e.g., azithromycin, doxycycline, or amoxicillin-clavulanate for 5–7 days).

---

Diabetes Mellitus (Type 1 vs. Type 2) Management

Diabetes management in nursing case management balances rigorous glycemic control to prevent long-term microvascular and macrovascular destruction against the immediate, life-threatening dangers of treatment-induced hypoglycemia.

Clinical & Pathophysiological Comparison

Diagnostic Criteria (ADA Standards of Care)

• Fasting Plasma Glucose (FPG): ≥126 mg/dL (fasting defined as no caloric intake for at least 8 hours).
• 2-Hour Plasma Glucose (OGTT): ≥200 mg/dL during a 75-gram oral glucose tolerance test.
• Glycated Hemoglobin (HbA1c): ≥6.5% using a National Glycohemoglobin Standardization Program (NGSP) certified assay.
• Random Plasma Glucose: ≥200 mg/dL in an individual presenting with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss) or hyperglycemic crisis. (Unless unambiguous symptoms of acute hyperglycemia are present, diagnosis requires two abnormal test results from the same sample or separate test samples).

Individualized Glycemic Targets (HbA1c)

The American Diabetes Association (ADA) emphasizes that glycemic targets must be rigorously individualized based on patient-specific risk profiles:

• Standard Adult Target (<7.0%): Recommended for most nonpregnant, cognitively intact adults with substantial life expectancy and low hypoglycemia risk.
• More Stringent Target (<6.5%): Appropriate for select individuals (short disease duration, young age, long life expectancy, treated with lifestyle or metformin alone) if achievable without significant hypoglycemia or treatment burden.
• Less Stringent Target (<8.0% or <8.5%): Mandated for complex older adults, patients with extensive comorbidities, history of severe hypoglycemia, hypoglycemia unawareness, established advanced microvascular/macrovascular complications, or limited remaining life expectancy. High-Yield Exam Trap: Aggressive A1c lowering (<6.5%) in frail older adults with cardiovascular disease significantly increases all-cause mortality driven by hypoglycemia-induced ventricular dysrhythmias and falls.

Cardiorenal Protective Pharmacotherapy in T2D

Modern guidelines dictate that pharmacotherapy selection in Type 2 Diabetes is guided by organ protection rather than glucose-lowering potency alone:

• SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): Strongly indicated for patients with established Heart Failure (regardless of ejection fraction) and Chronic Kidney Disease (eGFR 20–60 mL/min/1.73m² or persistent albuminuria), slowing renal decline and reducing cardiovascular death.
• GLP-1 Receptor Agonists (Semaglutide, Dulaglutide, Liraglutide): Preferred for patients with established Atherosclerotic Cardiovascular Disease (ASCVD) (prior MI, stroke, CAD, PAD) or high cardiovascular risk, providing robust stroke and MI risk reduction and significant weight loss.

Hypoglycemia Management & The Standardized "Rule of 15"

Hypoglycemia is clinically defined as blood glucose <70 mg/dL (Level 1) or <54 mg/dL (Level 2: clinically significant). Symptoms manifest as neurogenic/adrenergic (diaphoresis, tremors, tachycardia, palpitations, anxiety, hunger) and neuroglycopenic (confusion, dizziness, blurred vision, dysarthria, seizure, coma).

┌────────────────────────────────────────────────────────────────────────┐
│                     THE HYPOGLYCEMIA "RULE OF 15"                      │
├────────────────────────────────────────────────────────────────────────┤
│ STEP 1: IDENTIFY                                                       │
│ Check capillary blood glucose: confirmed <70 mg/dL (or symptomatic).  │
│                                                                        │
│ STEP 2: TREAT                                                          │
│ Administer 15 grams of FAST-ACTING, SIMPLE CARBOHYDRATES:              │
│   • 4 ounces (1/2 cup) fruit juice (orange, apple)                     │
│   • 4 ounces (1/2 cup) regular (non-diet) soda                         │
│   • 3 to 4 commercial glucose tablets                                  │
│   • 1 tube commercial glucose gel                                      │
│   • 1 tablespoon table sugar or honey dissolved in water               │
│   *CRITICAL RULE:* NEVER use chocolate, milk, cake, or ice cream!      │
│   Fat severely blunts and delays gastric absorption of glucose.        │
│                                                                        │
│ STEP 3: WAIT                                                           │
│ Rest quietly for 15 minutes. Do not eat additional food.               │
│                                                                        │
│ STEP 4: RECHECK & RE-TREAT                                             │
│ Recheck blood glucose after 15 minutes:                                │
│   • If STILL <70 mg/dL: Administer another 15 grams of simple carbs,   │
│     wait 15 minutes, and recheck.                                      │
│   • If ≥70 mg/dL: If the next scheduled meal is >1 hour away, provide  │
│     a snack containing complex carbohydrates AND protein               │
│     (e.g., peanut butter crackers, cheese and toast) to sustain blood  │
│     glucose and replenish hepatic glycogen reserves.                   │
└────────────────────────────────────────────────────────────────────────┘

• Severe Hypoglycemia (Level 3): Characterized by altered mental status, unconsciousness, or seizures requiring third-party assistance. Emergency treatment requires Glucagon (1 mg IM/SubQ, or nasal glucagon powder [Baqsimi] 3 mg intranasally) or IV 50% Dextrose (D50W 25–50 mL). Case managers must ensure that every insulin-treated patient has an unexpired glucagon prescription and that family/caregivers are trained in emergency administration.

Diabetic Sick-Day Management Protocols

Acute illness, infection, and surgical stress trigger a counter-regulatory hormonal surge (cortisol, epinephrine, glucagon) that drives acute hyperglycemia and ketogenesis. Case managers must educate patients on five cardinal Sick-Day Rules:

1. Never Discontinue Basal Insulin: Even if the patient is nauseated, anorexic, or vomiting, basal insulin must be continued to suppress lipolysis and prevent diabetic ketoacidosis (DKA). Bolus insulin may be adjusted based on actual oral intake.
2. Frequent Glucose Monitoring: Check blood glucose at least every 2 to 4 hours throughout the day and night.
3. Urine or Blood Ketone Testing: In patients with Type 1 Diabetes (or ketosis-prone T2D), check ketones every 4 hours whenever blood glucose exceeds 240 mg/dL or when vomiting occurs.
4. Hydration and Carbohydrate Maintenance: Consume at least 8 ounces (240 mL) of fluid every hour while awake. If blood glucose is elevated, drink calorie-free fluids (water, broth). If blood glucose is falling or the patient cannot eat solid food, consume carbohydrate-containing liquids (fruit juice, sports drinks, gelatin) to provide 15g carbs per hour and prevent hypoglycemia.
5. Provider Escalation Triggers: Contact the case manager or physician immediately if: vomiting persists >4 hours; inability to retain liquids; moderate-to-large ketones in urine/blood; blood glucose remains >250 mg/dL despite supplemental correction doses; or temperature exceeds 101.5°F (38.6°C).

Annual Preventive Surveillance Triad

To detect and halt insidious microvascular and macrovascular pathology, case managers track three annual surveillance measures:

1. Dilated Eye Examination: Annual dilated funduscopic exam by an optometrist or ophthalmologist to detect asymptomatic diabetic retinopathy.
2. Comprehensive Diabetic Foot Examination: Visual inspection, palpation of dorsalis pedis and posterior tibial pulses, evaluation of protective sensation using a 10-gram Semmes-Weinstein monofilament, and checking for deformities (hammer toes, Charcot foot). Loss of protective sensation (LOPS) mandates prescription orthotics and podiatric debridement.
3. Renal Surveillance: Annual random spot urine albumin-to-creatinine ratio (uACR) combined with serum creatinine/eGFR to detect early diabetic nephropathy.

---

Chronic Kidney Disease (CKD) Management

Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function persisting for >3 months. Case managers classify and navigate CKD using the KDIGO (Kidney Disease: Improving Global Outcomes) classification system.

The KDIGO CKD Classification Matrix

The KDIGO framework stratifies CKD by combining Glomerular Filtration Rate (GFR categories G1–G5) with Persistent Albuminuria (categories A1–A3), creating an evidence-based heat map of risk for CKD progression, cardiovascular events, and mortality:

┌────────────────────────────────────────────────────────────────────────┐
│                     KDIGO CKD STAGING & RISK MATRIX                    │
├──────────────────────────┬─────────────────────────────────────────────┤
│ GFR Stage (mL/min/1.73m²) │ Persistent Albuminuria (uACR in mg/g)       │
│                          │ A1: Normal (<30) | A2: Mod (30-300) | A3: >300│
├──────────────────────────┼──────────────────┼──────────────────┼───────┤
│ G1: Normal/High (≥90)    │ Low Risk         │ Moderate Risk    │ High  │
│ G2: Mildly Decreased (60)│ Low Risk         │ Moderate Risk    │ High  │
│ G3a: Mild-Mod (45-59)    │ Moderate Risk    │ High Risk        │ V.High│
│ G3b: Mod-Severe (30-44)  │ High Risk        │ Very High Risk   │ V.High│
│ G4: Severely Decreased   │ Very High Risk   │ Very High Risk   │ V.High│
│     (15-29)              │                  │                  │       │
│ G5: Kidney Failure (<15) │ Very High Risk   │ Very High Risk   │ V.High│
└──────────────────────────┴──────────────────┴──────────────────┴───────┘

Cardiorenal Protection & Nephrotoxic Drug Elimination

1. Blood Pressure Optimization & Renoprotection: Strict blood pressure control (<120 mmHg standardized systolic per KDIGO; <130/80 mmHg per ACC/AHA). ACE inhibitors or ARBs are first-line for patients with hypertension and albuminuria (uACR ≥30 mg/g) because they preferentially dilate efferent glomerular arterioles, reducing intraglomerular hydrostatic pressure and decreasing proteinuria.
2. Nephrotoxic Medication Elimination: The case manager must conduct rigorous, ongoing medication reconciliation to eliminate all nephrotoxins:
   • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, naproxen, meloxicam, and high-dose aspirin are strictly contraindicated in CKD. NSAIDs inhibit cyclooxygenase (COX), blocking vasodilatory renal prostaglandins. This causes unopposed afferent arteriolar vasoconstriction, abruptly dropping glomerular perfusion and precipitating acute-on-chronic renal failure.
   • Intravenous Iodinated Radiocontrast: High risk of contrast-induced nephropathy (CIN). When imaging is essential, ensure volume expansion with intravenous isotonic saline (0.9% NaCl) pre- and post-procedure; avoid repetitive imaging.
   • Aminoglycoside Antibiotics: Gentamicin, tobramycin, and amikacin cause direct proximal tubular necrosis; require therapeutic drug monitoring and dose adjustments.
   • Metformin Safety Mandate: Discontinue metformin when eGFR drops below 30 mL/min/1.73m² (and do not initiate if eGFR <45 mL/min/1.73m²) to prevent fatal lactic acidosis.

Renal Replacement Therapy (RRT) Preparation & Non-Dominant Arm Vein Preservation

When a patient's kidney function deteriorates to Stage G4 CKD (eGFR <30 mL/min/1.73m²), the case manager must initiate multidisciplinary planning for renal replacement therapy:

• Modality Education: Educate the patient and family on the clinical and lifestyle differences between In-Center Hemodialysis (HD), Home Hemodialysis (HHD), Peritoneal Dialysis (PD) (continuous ambulatory vs. automated cycler), and Pre-Emptive Kidney Transplantation (the gold standard for eligible candidates, ideally performed prior to dialysis initiation).
• Arteriovenous (AV) Fistula as Gold Standard: For hemodialysis, an autogenous arteriovenous (AV) fistula (typically cephalic vein to radial or brachial artery) is vastly superior to arteriovenous grafts (AVG) or central venous hemodialysis catheters (tunneled PermCaths). AV fistulas demonstrate the highest long-term patency rates, lowest thrombosis rates, and dramatically lower rates of catheter-related bloodstream infections (CRBSI) and sepsis. However, an AV fistula requires 6 to 12 months to mature (develop adequate wall hypertrophy and luminal dilation to support high-flow dialysis cannulation). Therefore, surgical referral must occur during Stage G4.
• Strict Vein Preservation Protocol: To preserve viable superficial veins for fistula creation, the case manager must implement and enforce a non-negotiable Vein Preservation Protocol for the patient's non-dominant arm:
  • NO venipunctures (blood draws) in the non-dominant forearm or antecubital fossa.
  • NO peripheral intravenous (IV) catheters or midline catheters in the non-dominant arm.
  • NO blood pressure cuffs or arterial lines on the non-dominant arm.
  • Place a bright, standardized "Limb Alert / Save the Vein" wristband on the non-dominant arm.
  • Educate the patient to become an active advocate, instructing phlebotomists and nurses to utilize only the dorsum of the hand or the dominant arm for required venous access.

---

Clinical Case Scenario: Comprehensive GDMT & Care Transition Optimization

Patient History & Presentation

A 67-year-old male with a 12-year history of Type 2 Diabetes, hypertension, and Stage G3b A2 CKD (baseline eGFR 38 mL/min/1.73m², uACR 180 mg/g) is admitted to the progressive cardiac care unit with acute decompensated heart failure. Diagnostic echocardiography reveals an LVEF of 30% with diffuse left ventricular hypokinesis (MS-DRG 292: Heart Failure and Shock with CC; CMS GMLOS benchmark = 3.2 days).

Inpatient Hospital Course & Clinical Stabilization

• Days 1–3: The patient receives IV furosemide infusions. His admission weight decreases by 4.2 kg, resolving bibasilar crackles and lower-extremity edema. His discharge dry weight is established at 88.0 kg (194 lbs). Serum creatinine is stable at 1.9 mg/dL (eGFR 36 mL/min/1.73m²), and potassium is 4.3 mEq/L.
• Discharge Regimen Planning (GDMT Optimization): The cardiology team orders sacubitril/valsartan (ARNI) 24/26 mg twice daily, metoprolol succinate extended-release 25 mg daily, empagliflozin (SGLT2i) 10 mg daily, and oral furosemide 40 mg daily.
• Case Management Safety Interventions:
  1. Washout Verification: The case manager notes the patient was taking lisinopril 20 mg daily at home. The case manager verifies that the last dose of lisinopril was given on Day 2 at 08:00. The first dose of sacubitril/valsartan is scheduled for Day 3 at 20:00, strictly fulfilling the mandatory 36-hour washout period to eliminate angioedema risk.
  2. Hypoglycemia Prevention: The case manager reviews the patient's diabetes regimen (metformin was appropriately discontinued due to CKD progression). Insulin glargine is reduced by 20% to account for reduced caloric intake, and the case manager provides Teach-Back education on the Rule of 15.
  3. Transition & DME Logistics: The case manager orders a digital bathroom scale through DME benefits, provides a written Stoplight Heart Failure Action Plan, schedules an outpatient cardiology follow-up appointment for Post-Discharge Day 5, and enrolls the patient in telephonic transitional care management.

Post-Discharge Telephone Encounter (Day 3 Post-Discharge)

During the scheduled 72-hour transitional telephone follow-up, the nurse case manager reviews the patient's morning weight log:

• Discharge Dry Weight: 88.0 kg (194.0 lbs)
• Post-Discharge Day 1: 88.1 kg (194.2 lbs)
• Post-Discharge Day 2: 88.4 kg (194.8 lbs)
• Post-Discharge Day 3: 89.6 kg (197.5 lbs) — a 2.7 lb weight gain in 24 hours (Yellow Zone).
• Patient reports mild shortness of breath when walking to the kitchen and needing two pillows to sleep flat.

Case Manager Execution

1. Immediate Clinical Action: The case manager identifies the Yellow Zone alert (>2 lbs overnight gain + orthopnea). Rather than advising emergency room presentation, the case manager immediately contacts the cardiology clinic provider to activate the pre-established outpatient contingency protocol: doubling oral furosemide from 40 mg to 80 mg daily for 2 days.
2. Dietary Barrier Assessment: The case manager discovers the patient's family brought him canned chicken noodle soup (1,800 mg sodium per serving) following discharge. The case manager reinforces the <2,000 mg/day sodium restriction and provides concrete low-sodium seasoning alternatives.
3. Outcome: At the Day 5 clinic follow-up, the patient's weight returns to 88.2 kg, orthopnea resolves, and acute 30-day hospital readmission is successfully prevented.

---

Common Exam Traps & High-Yield Takeaways

• Exam Trap 1: Failing to Enforce the 36-Hour Washout for ACEI to ARNI. Never select an answer that starts sacubitril/valsartan immediately following an ACE inhibitor. A 36-hour drug-free interval is non-negotiable to avoid massive bradykinin accumulation and fatal angioedema. Switching from an ARB to an ARNI requires zero washout time.
• Exam Trap 2: Inappropriate Use of Inhaled Corticosteroid Monotherapy in COPD. ICS monotherapy is strictly contraindicated in COPD; it does not alter disease progression and significantly raises pneumonia risk. ICS must only be part of triple therapy (LABA+LAMA+ICS) in Group E patients with a blood eosinophil count ≥300 cells/µL.
• Exam Trap 3: Aggressive Glycemic Lowering in Complex Older Adults. On the exam, do not select an A1c target of <6.5% for frail older adults with established cardiovascular disease, chronic kidney disease, or dementia. The correct target is <8.0% or <8.5% to prevent lethal hypoglycemia-induced dysrhythmias and traumatic falls.
• Exam Trap 4: Treating Hypoglycemia with Fat-Containing Foods. When selecting foods for the Rule of 15, avoid chocolate, candy bars, milk, or baked goods. Dietary fat delays gastric emptying and markedly slows carbohydrate absorption. Select 15g of simple, rapidly absorbed carbohydrates: 4 oz fruit juice, 4 oz regular soda, or 3–4 glucose tablets.
• Exam Trap 5: Ignoring Non-Dominant Arm Vein Preservation in CKD. When managing a patient with Stage G4 CKD (eGFR <30 mL/min/1.73m²), any procedure involving IV placement, venipuncture, or blood pressure measurement on the non-dominant arm is incorrect. Strict vein preservation is paramount to safeguard vessels for an upcoming arteriovenous fistula.